Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2008-11-7
pubmed:abstractText
Genetic and epigenetic plasticity allows tumors to evade single-targeted treatments. Here we direct Bcl2-specific short interfering RNA (siRNA) with 5'-triphosphate ends (3p-siRNA) against melanoma. Recognition of 5'-triphosphate by the cytosolic antiviral helicase retinoic acid-induced protein I (Rig-I, encoded by Ddx58) activated innate immune cells such as dendritic cells and directly induced expression of interferons (IFNs) and apoptosis in tumor cells. These Rig-I-mediated activities synergized with siRNA-mediated Bcl2 silencing to provoke massive apoptosis of tumor cells in lung metastases in vivo. The therapeutic activity required natural killer cells and IFN, as well as silencing of Bcl2, as evidenced by rescue with a mutated Bcl2 target, by site-specific cleavage of Bcl2 messenger RNA in lung metastases and downregulation of Bcl-2 protein in tumor cells in vivo. Together, 3p-siRNA represents a single molecule-based approach in which Rig-I activation on both the immune- and tumor cell level corrects immune ignorance and in which gene silencing corrects key molecular events that govern tumor cell survival.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1546-170X
pubmed:author
pubmed-author:AkiraShizuoS, pubmed-author:AnzDavidD, pubmed-author:BerkingCarolaC, pubmed-author:BeschRobertR, pubmed-author:BourquinCaroleC, pubmed-author:BscheiderMichaelM, pubmed-author:BuschDirkD, pubmed-author:EndresStefanS, pubmed-author:GaffalEvelynE, pubmed-author:HäckerGeorgG, pubmed-author:HartmannGuntherG, pubmed-author:HellmuthJohannesJ, pubmed-author:HornungVeitV, pubmed-author:KalinkeUlrichU, pubmed-author:KatoHirokiH, pubmed-author:KirschnekSusanneS, pubmed-author:KremmerElisabethE, pubmed-author:LandsbergJenniferJ, pubmed-author:MaihoeferCorneliusC, pubmed-author:MeyersRachelR, pubmed-author:MorskayaSvetlana ShulgaSS, pubmed-author:NeuenhahnMichaelM, pubmed-author:PoeckHendrikH, pubmed-author:PrinzMarcoM, pubmed-author:RennMarcelM, pubmed-author:RothenfusserSimonS, pubmed-author:RulandJürgenJ, pubmed-author:SchmidtAndreasA, pubmed-author:SchwerdTobiasT, pubmed-author:TütingThomasT, pubmed-author:TormoDamiaD
pubmed:issnType
Electronic
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1256-63
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:18978796-Animals, pubmed-meshheading:18978796-Antineoplastic Agents, pubmed-meshheading:18978796-Apoptosis, pubmed-meshheading:18978796-Cell Line, Tumor, pubmed-meshheading:18978796-Cell Transplantation, pubmed-meshheading:18978796-DEAD-box RNA Helicases, pubmed-meshheading:18978796-Disease Models, Animal, pubmed-meshheading:18978796-Enzyme Activation, pubmed-meshheading:18978796-Female, pubmed-meshheading:18978796-Gene Expression Regulation, Neoplastic, pubmed-meshheading:18978796-Gene Silencing, pubmed-meshheading:18978796-Humans, pubmed-meshheading:18978796-Immunity, Innate, pubmed-meshheading:18978796-Melanoma, pubmed-meshheading:18978796-Mice, pubmed-meshheading:18978796-Phosphates, pubmed-meshheading:18978796-Proto-Oncogene Proteins, pubmed-meshheading:18978796-RNA, Small Interfering
pubmed:year
2008
pubmed:articleTitle
5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma.
pubmed:affiliation
Institute of Clinical Chemistry and Pharmacology, University Hospital, University of Bonn, Bonn, Germany.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't